title: [Progress on study of achromatopsia and targeted gene therapy].
abstract: Achromatopsia is an early onset retinal dystrophy that causes severe visual impairment. To date, four genes have been found to be implicated in achromatopsia-associated mutations: guanine nucleotide-binding protein (GNAT2), cyclic nucleotide-gated channel alpha-3 (CNGA3), cyclic nucleotide-gated channel beta-3 (CNGB3) and phosphodiesterase 6C (PDE6C). Even with early onset, the slow progress and the good responses to gene therapy in animal models render achromatopsia a very attractive candidate for human gene therapy after the successful of the Phase I clinical trials of Leber's congenital amaurosis. With the development of molecular genetics and the therapeutic gene replacement technology, the adeno-associated viral (AAV) vector-mediated gene therapy for achromatopsia in the preclinical animal experiments achieved encouraging progress in the past years. This article briefly reviews the recent research achievements of achromatopsia with gene therapy.
authors.affiliation: School of Optometry and Ophthalmology, Wenzhou Medical College, Wenzhou, China.
authors.forename: Xu-feng
authors.initials: XF
authors.lastname: Dai
authors.forename: Ji-jing
authors.initials: JJ
authors.lastname: Pang
mesh_terms: D003117:Color Vision Defects / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans